Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methocarbamol is a centrally acting skeletal muscle relaxant used to relieve discomfort associated with acute musculoskeletal conditions such as muscle pain or injury. It is often prescribed alongside rest and physical therapy. The precise mechanism of action is not fully understood but is believed to involve central nervous system depression by blocking nerve impulses or pain sensations sent to the brain. Methocarbamol may also block spinal polysynaptic reflexes and decrease nerve transmission in spinal and supraspinal pathways. It does not act directly on skeletal muscle fibers or motor end plates. Methocarbamol can be administered orally or by injection; the injectable form may also be used in the management of tetanus (lockjaw)[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methocarbamol.